SLC2A1 and prostate cancer: In agreement, we report a vulnerability to the GLUT1 inhibitor BAY-876 in both chronic hypoxia and castration-resistant prostate cancer cells, revealing a therapeutically targetable weakness arising under chronic hypoxia.